HDHan Dong

Han Dong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Han Dong has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Ursula A. Matulonis

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    2 shared publications
  • Alaa Kassim Ali

    Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    1 shared publication
  • Amy Cameron

    Dana-Farber Cancer Institute Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology Boston, Massachusetts

    1 shared publication
  • Andreia Maia

    Dana-Farber Cancer Institute 2 Boston, MA

    1 shared publication
  • Arindam Ray

    Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA

    1 shared publication
  • Chayapatou Chayawatto

    Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    1 shared publication

Latest Publications

  • Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer

    by Han Dong, Arindam Ray, Lara K. Rotter, Jinhua Wang, Isabella Grabski, Heemaja Mewada, Lulu Wang, Kun Huang, Ye Tian, Maxime Meylan, et al.

    Patients with metastatic high-grade serous ovarian carcinoma are often unresponsive to immunotherapies; here we identify salt-inducible kinases (SIKs) as key drivers of immunosuppression. Human T cells in the presence of patient ascites express high levels of SIK and the upstream kinase LKB1, whereas SIK inhibition reprograms human T cells and strongly activates antitumor responses. In syngeneic mice with resistant high-grade serous ovarian carcinoma, genetic ablation and pharmaceutical inhibition of SIK consistently demonstrated therapeutic efficacy and survival advantages, and combination of PD-1 blockade with SIK inhibition further extended survival. We identified a major role of T cell-intrinsic SIK2 and -3 signaling in driving immunosuppression in part by TXNIP induction and LYST suppression. Multi-omics analyses on SIK inhibitor therapy revealed reduced disease progression, increased T cell infiltration with enhanced cytotoxicity and effector cytokine IFN-γ, and a shift from immunosuppressive to immunostimulatory cellular niche. We propose SIK inhibitors as a new immunotherapy.


  • Open Access

    CAR memory–like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer

    by Mubin Tarannum, Khanhlinh Dinh, Juliana Vergara, Grace Birch, Yasmin Z. Abdulhamid, Isabel E. Kaplan, Oyku Ay, Andreia Maia, Owen Beaver, Michal Sheffer, et al.

    Epithelial ovarian cancer (EOC) remains one of the most lethal gynecological cancers. Cytokine-induced memory–like (CIML) natural killer (NK) cells have shown promising results in preclinical and early-phase clinical trials. In the current study, CIML NK cells demonstrated superior antitumor responses against a panel of EOC cell lines, increased expression of activation receptors, and up-regulation of genes involved in cell cycle/proliferation and down-regulation of inhibitory/suppressive genes. CIML NK cells transduced with a chimeric antigen receptor (CAR) targeting the membrane-proximal domain of mesothelin (MSLN) further improved the antitumor responses against MSLN-expressing EOC cells and patient-derived xenograft tumor cells. CAR arming of the CIML NK cells subtanstially reduced their dysfunction in patient-derived ascites fluid with transcriptomic changes related to altered metabolism and tonic signaling as potential mechanisms. Lastly, the adoptive transfer of MSLN-CAR CIML NK cells demonstrated remarkable inhibition of tumor growth and prevented metastatic spread in xenograft mice, supporting their potential as an effective therapeutic strategy in EOC.


  • Open Access

    Sfrp4 is required to maintain Ctsk-lineage periosteal stem cell niche function

    by Ruiying Chen, Han Dong, Dhairya Raval, David Maridas, Sudipta Baroi, Kun Chen, Dorothy Hu, Shawn R. Berry, Roland Baron, Matthew B. Greenblatt, et al.

    We have previously reported that the cortical bone thinning seen in mice lacking the Wnt signaling antagonistSfrp4is due in part to impaired periosteal apposition. The periosteum contains cells which function as a reservoir of stem cells and contribute to cortical bone expansion, homeostasis, and repair. However, the local or paracrine factors that govern stem cells within the periosteal niche remain elusive. Cathepsin K (Ctsk), together with additional stem cell surface markers, marks a subset of periosteal stem cells (PSCs) which possess self-renewal ability and inducible multipotency.Sfrp4is expressed in periosteal Ctsk-lineage cells, andSfrp4global deletion decreases the pool of PSCs, impairs their clonal multipotency for differentiation into osteoblasts and chondrocytes and formation of bone organoids. Bulk RNA sequencing analysis of Ctsk-lineage PSCs demonstrated thatSfrp4deletion down-regulates signaling pathways associated with skeletal development, positive regulation of bone mineralization, and wound healing. Supporting these findings,Sfrp4deletion hampers the periosteal response to bone injury and impairs Ctsk-lineage periosteal cell recruitment. Ctsk-lineage PSCs express the PTH receptor and PTH treatment increases the % of PSCs, a response not seen in the absence ofSfrp4. Importantly, in the absence ofSfrp4, PTH-dependent increase in cortical thickness and periosteal bone formation is markedly impaired. Thus, this study provides insights into the regulation of a specific population of periosteal cells by a secreted local factor, and shows a central role for Sfrp4 in the regulation of Ctsk-lineage periosteal stem cell differentiation and function.